That Sound You Hear is the Illusion Shattering

https://thehighwire.com/ark-videos/peter-marks-exposed/

Effectiveness of the Influenza Vaccine During the 2024-2025 Respiratory Viral Season

Cleveland Clinic Study Reveals Higher COVID-19 Rates With More Boosters

Postacute sequelae of SARS-CoV-2 in the population: Risk factors and vaccines

The contribution of pre-existing conditions to severe versus mild postacute sequelae (PASC) of SARS-CoV-2 in the population is lacking.

Vaccinated men and women were more likely to report poor sleep quality (24.26% vs 17.98 (Men), 30.12% vs 21.48% (Women), p=0.039 for sex and p=0.015 for vaccination status) and trouble concentrating (35.69% vs 26.91% (Men), 49.44% vs 36.52% (Women)) compared to unvaccinated counterparts as PASC.

More women reported vaccine-associated AEs than men after the 1^st dose (60.85% vs 48.79%, p<0.01, Fig. 2c) and vaccinated individuals reported experiencing more frequent COVID-19 symptoms than unvaccinated respondents after 1^st SARS-CoV-2 infection (Fig. 2d and Extended Data Fig. 2 and Extended Data Table 2).

Vaccinated COVID-19 respondents were significantly less likely than unvaccinated COVID-19 respondents to develop the following reported post-COVID symptoms: fatigue/tiredness (aHR = 0.25), change/loss of smell and taste (aHR = 0.59 and 0.67, respectively), fever (aHR = 0.38), body and/or muscle aches (aHR = 0.35), nasal stuffiness (aHR = 0.84), chills (aHR = 0.62), and headache (aHR = 0.44), whereas vaccinated individuals were more likely to develop and reported eye soreness (aHR = 3.05), cough (aHR = 2.24), dyspnea (aHR = 3.61), trouble breathing (aHR= 1.85), sleeping more (aHR = 1.95), new confusion/inability to fully awake (aHR = 1.41), hospitalization (aHR = 1.25), intubation/ventilation (aHR = 1.15), and pneumonia (aHR = 1.4) amongst other reported symptoms (Fig. 2e and Extended Data Table 3).

Vaccine AE-associated hospitalization was reported by 6.24% (56/898) individuals compared with 1.06% (25/2351) of unvaccinated individuals with COVID-19 (Fig. 2f, p=0.015).

No reproductive adverse events were reported by 82.75% of unvaccinated females and 98.32% of males after COVID-19 illness vs 60.39% of vaccinated females and 93.62% of males (p=0.00016 and p=0.04, respectively) (Table 3). Hormonal changes and sexual dysfunction were reported by 2.13% vs 0% (p=0.011) and 3.4% vs 0.67% (p=0.04) of vaccinated men versus unvaccinated men after 1^st SARS-CoV-2 infection (Table 3). Vaccinated women reported higher incidence of hormonal changes, absence of periods, irregular or heavy periods, and hot flashes compared with unvaccinated women after 1^st SARS-CoV-2 infection (Table 3).